AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating

Virology

Volumn 454-455, Issue 1, 2014, Pages 227-236

  Tenney, Rebeca M ^a   Bell, Christie L ^a   Wilson, James M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AAV8; Capsid structure; Chimera; Gene therapy; Liver; Uncoating

Indexed keywords

ADENOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CHIMERA; CONTROLLED STUDY; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS ENTRY; VIRUS MORPHOLOGY; VIRUS NUCLEOCAPSID; VIRUS UNCOATING;

AAV8; CAPSID STRUCTURE; CHIMERA; GENE THERAPY; LIVER; UNCOATING;

ANIMALS; CAPSID PROTEINS; CELL NUCLEUS; DEPENDOVIRUS; LIVER; MALE; MICE; MICE, INBRED C57BL; TRANSDUCTION, GENETIC; VIRUS UNCOATING;

EID: 84895987316     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.02.017     Document Type: Article

References (38)

1. Akache B., Grimm D., Shen X., Fuess S., Yant S.R, Glazer D.S, Park J., Kay M.A A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol. Ther 2007, 15:330-339.
2. Asokan A., Conway J.C, Phillips J.L, Li C., Hegge J., Sinnott R., Yadav S., DiPrimio N., Nam H.-J., Agbandje-McKenna M., McPhee S., Wolff J., Samulski R.J Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 2009, 28:79-82.
3. Bartlett J.S, Samulski R.J, McCown T.J Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum. Gene Ther. 1998, 9:1181-1186.
4. Bowles D.E., McPhee S.W., Li C., Gray S.J., Samulski J.J., Camp A.S., Li J., Wang B., Monahan P.E., Rabinowitz J.E., Grieger J.C., Govindasamy L., Agbandje-McKenna M., Xiao X., Samulski R.J. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 2012, 20(2):443-455. 10.1038/mt.2011.237.
5. Calcedo R., Vandenberghe L.H, Gao G., Lin J., Wilson J.M Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 2009, 199:381-390.
6. DiMattia M.A, Nam H.-J., Van Vliet K., Mitchell M., Bennett A., Gurda B.L, McKenna R., Olson N.H, Sinkovits R.S, Potter M., Byrne B.J, Aslanidi G., Zolotukhin S., Muzyczka N., Baker T.S, Agbandje-McKenna M. Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 2012, 86:6947-6958.
7. Gao G.-P., Alvira M.R, Wang L., Calcedo R., Johnston J., Wilson J.M Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 2002, 99:11854-11859.
8. Govindasamy L., Padron E., McKenna R., Muzyczka N., Kaludov N., Chiorini J.A, Agbandje-McKenna M. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 2006, 80:11556-11570.
9. Gurda B.L, Raupp C., Popa-Wagner R., Naumer M., Olson N.H, Ng R., McKenna R., Baker T.S, Kleinschmidt J.A, Agbandje-McKenna M. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J. Virol. 2012, 86:7739-7751.
10. Hauck B., Xiao W. Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol. 2003, 77:2768-2774.
11. Horton R.M, Cai Z.L, Ho S.N, Pease L.R Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. BioTechniques 1990, 8:528-535.
12. Hurlbut G.D, Ziegler R.J, Nietupski J.B, Foley J.W, Woodworth L.A, Meyers E., Bercury S.D, Pande N.N, Souza D.W, Bree M.P, Lukason M.J, Marshall J., Cheng S.H, Scheule R.K Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther. 2010, 18:1983-1994.
13. Johnson J.S, Samulski R.J Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J. Virol. 2009, 83:2632-2644.
14. Kotchey N.M, Adachi K., Zahid M., Inagaki K., Charan R., Parker R.S, Nakai H. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol. Ther. 2011, 19:1079-1089.
15. Kotin R.M. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum. Gene Ther. 1994, 5:793-801.
16. Lochrie M.A, Tatsuno G.P, Christie B., McDonnell J.W, Zhou S., Surosky R., Pierce G.F., Colosi P. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 2005, 80:821-834.
17. Lock M., Alvira M., Vandenberghe L.H, Samanta A., Toelen J., Debyser Z., Wilson J.M Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum. Gene Ther. 2010, 21:1259-1271.
18. Louboutin J.-P., Wang L., Wilson J.M Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med. 2005, 7:442-451.
19. McCraw D.M, O'Donnell J.K, Taylor K.A, Stagg S.M, Chapman M.S Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology 2012, 431:40-49.
20. Nakai H., Thomas C.E, Storm T.A, Fuess S., Powell S., Wright J.F, Kay M.A, Limited A. Number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J. Virol. 2002, 76:11343-11349.
21. Nam H.-J., Lane M.D, Padron E., Gurda B., McKenna R., Kohlbrenner E., Aslanidi G., Byrne B., Muzyczka N., Zolotukhin S., Agbandje-McKenna M. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 2007, 81:12260-12271.
22. Nam H.-J., Gurda B.L, McKenna R., Potter M., Byrne B., Salganik M., Muzyczka N., Agbandje-McKenna M. Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking. J. Virol. 2011, 85:11791-11799.
23. Opie S.R, Warrington K.H, Agbandje-McKenna M., Zolotukhin S., Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 2003, 77:6995-7006.
24. O'Donnell J., Taylor K.A, Chapman M.S Adeno-associated virus-2 and its primary cellular receptor-cryo-EM structure of a heparin complex. Virology 2009, 385:434-443.
25. Raupp C., Naumer M., Muller O.J, Gurda B.L, Agbandje-McKenna M., Kleinschmidt J.A The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J. Virol. 2012, 86:9396-9408.
26. Salganik M., Venkatakrishnan B., Bennett A., Lins B., Yarbrough J., Muzyczka N., Agbandje-McKenna M., McKenna R. Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J. Virol. 2012, 86:11877-11885.
27. Shen X., Storm T., Kay M.A Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency. Mol. Ther. 2007, 15:1955-1962.
28. Sipo I., Fechner H., Pinkert S., Suckau L., Wang X., Weger S., Poller W. Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction. Gene Ther. 2007, 14:1319-1329.
29. Thomas C.E, Storm T.A, Huang Z., Kay M.A Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 2004, 78:3110-3122.
30. Van Vliet K.M, Blouin V., Brument N., Agbandje-McKenna M., Snyder R.O The role of the adeno-associated virus capsid in gene transfer. Methods Mol. Biol. 2008, 437:51-91.
31. Vandenberghe L.H, Wilson J.M, Gao G. Tailoring the AAV vector capsid for gene therapy. Gene Ther. 2008, 16:311-319.
32. Vandenberghe L.H, Bell P., Maguire A.M, Cearley C.N, Xiao R., Calcedo R., Wang L., Castle M.J, Maguire A.C, Grant R., Wolfe J.H, Wilson J.M, Bennett J. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci. Transl. Med. 2011, 3:88ra54.
33. WU Z., Asokan A., SAMULSKI R. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 2006, 14:316-327.
34. Wang J., Xie J., Lu H., Chen L., Hauck B., Samulski R.J, Xiao W. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc. Natl. Acad. Sci. USA 2007, 104:13104-13109.
35. Wang L., Calcedo R., Nichols T.C, Bellinger D.A, Dillow A., Verma I.M, Wilson J.M Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 2005, 105:3079-3086.
36. Wobus C.E, Hügle-Dörr B., Girod A., Petersen G., Hallek M., Kleinschmidt J.A Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 2000, 74:9281-9293.
37. Xie Q., Bu W., Bhatia S., Hare J., Somasundaram T., Azzi A., Chapman M.S The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 2002, 99:10405-10410.
38. Zhong L., Li W., Yang Z., Qing K., Tan M., Hansen J., Li Y., Chen L., Chan R.J, Bischof D., Maina N., Weigel-Kelley K.A, Zhao W., Larsen S.H, Yoder M.C, Shou W., Srivastava A. Impaired nuclear transport and uncoating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary murine hematopoietic cells. Hum. Gene Ther. 2004, 15:1207-1218.